What is Foghorn Therapeutics Inc (FHTX) stock price today?

Foghorn Therapeutics Inc (FHTX) currently trades at $4.75 per share. The stock has a market capitalization of $311.70M and a P/E ratio of —x.

Is FHTX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Foghorn Therapeutics Inc has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Foghorn Therapeutics Inc's revenue and earnings?

Foghorn Therapeutics Inc has trailing twelve-month (TTM) revenue of $30.91M with profit margins of -240.30%. Earnings per share (EPS) is $-1.18.

FHTX

Foghorn Therapeutics Inc

NASDAQ: FHTX · HEALTHCARE · BIOTECHNOLOGY

$4.75

-0.21% today

Updated 2026-04-30

Market cap

$311.70M

P/E ratio

—

P/S ratio

10.08x

EPS (TTM)

$-1.18

Dividend yield

—

52W range

$3 – $7

Volume

0.2M

Market cap

$311.70M

P/E ratio

—

P/S ratio

10.08x

EPS (TTM)

$-1.18

Dividend yield

—

52W range

$3 – $7

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

7.3

Growth

B+

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$11.44

+140.84%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 223.80% QoQ

Risks

- Thin margins at -240.30%

- Negative free cash flow $-22.27M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$19.23M	$34.16M	$22.60M	$30.91M	$30.91M
Net income	$-108.87M	$-98.43M	$-86.62M	$-74.28M	$-21.66M
EPS	—	—	—	—	$-1.18
Free cash flow	$192.40M	$-119.33M	$-101.31M	$-86.15M	$-22.27M
Profit margin	-566.23%	-288.17%	-383.24%	-240.33%	-240.30%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-10	GOTTSCHALK, ADRIAN	Buy	59,208	—
2026-04-09	GOTTSCHALK, ADRIAN	Buy	47,497	—
2026-02-23	MAYNARD, RYAN D	Buy	400,000	$5.75

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
FHTX	$311.70M	28	7.3	2.0	5.0	5.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Foghorn Therapeutics Inc trades at $4.75. Our Smart Value Score of 28/100 indicates the stock is weak. TTM revenue stands at $30.91M. with profit margins at -240.30%.

Frequently asked questions

What is Foghorn Therapeutics Inc's stock price?

Foghorn Therapeutics Inc (FHTX) trades at $4.75.

Is Foghorn Therapeutics Inc overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Foghorn Therapeutics Inc (FHTX)?

The analyst target price is $11.44, representing +140.8% upside from the current price of $4.75.

What is Foghorn Therapeutics Inc's revenue?

TTM revenue is $30.91M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio10.08x

ROE-470.40%

Beta3.11

50D MA$5.21

200D MA$5.10

Shares out0.06B

Float0.03B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

FHTX vs LLY →FHTX vs JNJ →FHTX vs ABBV →Stock screener →